Article
Oncology
Andrew Dhawan, Venkata S. K. Manem, Gabrielle Yeaney, Justin D. Lathia, Manmeet S. Ahluwalia
Summary: We compared gene expression in primary and recurrent glioblastoma samples, focusing on those with EGFR amplification. Our results show that EGFR-amplified tumors have altered gene expression in the EGFR pathway, but this difference is lost in recurrent disease. EGFR pathway overexpression may be a common mechanism underlying glioblastoma recurrence.
Article
Biochemistry & Molecular Biology
Shaoyi Cai, Zhiyou Chen, Heng Tang, Siyan Meng, Liang Tao, Qin Wang
Summary: This study identified the crucial role of FKBP1A in GBM and its underlying molecular mechanism, showing that upregulated FKBP1A promotes GBM cell death through the apoptosis pathway, thereby inhibiting GBM growth.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Yuchuan Zhou, Hongxia Liu, Wang Zheng, Qianping Chen, Songling Hu, Yan Pan, Yang Bai, Jianghong Zhang, Chunlin Shao
Summary: Through cross-analysis of different databases, this study identified 11 survival-related genes in GBM patients, with the discovery that the MMP14 gene plays a key role in SAHA-induced radiosensitization of GBM.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biology
Youri Hoogstrate, Malgorzata A. Komor, Rene Bottcher, Job van Riet, Harmen J. G. van de Werken, Stef van Lieshout, Ralf Hoffmann, Evert van den Broek, Anne S. Bolijn, Natasja Dits, Daoud Sie, David van der Meer, Floor Pepers, Chris H. Bangma, Geert J. L. H. van Leenders, Marcel Smid, Pim J. French, John W. M. Martens, Wilbert van Workum, Peter J. van der Spek, Bart Janssen, Eric Caldenhoven, Christian Rausch, Mark de Jong, Andrew P. Stubbs, Gerrit A. Meijer, Remond J. A. Fijneman, Guido W. Jenster
Summary: The study developed an algorithm to accurately identify fusion genes using RNA-seq data, discovered new types of fusion transcripts, investigated the transcriptional effects of genomic breakpoints in tumors, and identified rearrangement hotspots in certain diseases. This approach has the potential to provide new insights into fusion gene research.
Editorial Material
Clinical Neurology
Alfredo Lucas, James H. Eberwine, Stephen J. Bagley, Yi Fan, MacLean Nasrallah, Steven Brem
Summary: The article was withdrawn due to a duplication error, and the definitive version is published under a specific DOI.
Article
Oncology
Shenbo Chen, Liangwang Yang, Zhengzheng Li, Shenghua Zhuo, Bo Yan, Zhaoteng Zhang, Jinben Zhang, Haizhong Feng, Kun Yang
Summary: EGFR/EGFR variant III (EGFRvIII) glioblastoma with co-expression of EGFR and GLUT3 is associated with worse overall survival. Experimental evidence suggests that EGFRvIII and GLUT3 cooperate in promoting tumorigenesis, indicating a potential therapeutic target.
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Xintao Jing, Cong Han, Qian Li, Fang Li, Jinyuan Zhang, Qiuyu Jiang, Fei Zhao, Chen Guo, Jinfeng Chen, Ting Jiang, Xiaofei Wang, Yanke Chen, Chen Huang
Summary: IGF2BP3 plays a crucial regulatory role in breast cancer cells and its targets are enriched in inflammatory response, endoplasmic reticulum stress, cell cycle, and cancer-related pathways. Additionally, IGF2BP3 promotes cancer cell proliferation through regulation of the EGFR/AKT pathway.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Justin Choi, Zachary A. Bordeaux, Jaimie McKeel, Cory Nanni, Nishadh Sutaria, Gabriella Braun, Cole Davis, Meghan N. Miller, Martin P. Alphonse, Shawn G. Kwatra, Cameron E. West, Madan M. Kwatra
Summary: This study examined the effect of a novel anti-cancer agent, GZ17-6.02, on two types of glioblastoma stem cells. The results showed that GZ17-6.02 inhibited cell growth and downregulated pathways related to steroid synthesis and cell cycle progression. Animal experiments also demonstrated that GZ17-6.02 inhibited glioblastoma growth. The study concludes that GZ17-6.02 is a promising drug for inhibiting the growth of a subset of glioblastomas.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Multidisciplinary
Rameshwar Patil, Tao Sun, Mohammad Harun Rashid, Liron L. Israel, Arshia Ramesh, Saya Davani, Keith L. Black, Alexander Ljubimov, Eggehard Holler, Julia Y. Ljubimova
Summary: This study aimed to develop multifunctional nanomedicines for treating glioblastoma using combination therapy targeting multiple molecular markers. By utilizing multifunctional nanopolymers, the growth of GBM cells was effectively inhibited, significantly increasing the survival rate of tumor-bearing animals.
Article
Oncology
Youwei Li, Dongsheng Guo
Summary: This study identified survival-related alternative splicing (AS) events in glioblastoma (GBM) and constructed an effective risk prediction model. The findings contribute to a better understanding of the AS mechanisms in GBM and provide new insights for further research. The risk prediction model shows promising performance in preliminary clinical applications, although further validation is needed.
Article
Oncology
Andres F. Cardona, Daniel Jaramillo-Velasquez, Alejandro Ruiz-Patino, Carolina Polo, Enrique Jimenez, Fernando Hakim, Diego Gomez, Juan Fernando Ramon, Hernando Cifuentes, Juan Armando Mejia, Fernando Salguero, Camila Ordonez, Alvaro Munoz, Sonia Bermudez, Nicolas Useche, Diego Pineda, Luisa Ricaurte, Zyanya Lucia Zatarain-Barron, July Rodriguez, Jenny Avila, Leonardo Rojas, Elvira Jaller, Carolina Sotelo, Juan Esteban Garcia-Robledo, Nicolas Santoyo, Christian Rolfo, Rafael Rosell, Oscar Arrieta
Summary: This study targeted adult patients with recurrent GB enriched for EGFR amplification and EGFRvIII mutation, using osimertinib/bevacizumab combination therapy, and found some patients experienced long-lasting meaningful benefits. Resistance patterns after treatment included known mechanisms in EGFR regulation, contributing to understanding and targeting this pathway in a rational stepwise manner.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Article
Oncology
Yan Mei, Xiumei Wang, Ji Zhang, Dan Liu, Junjie He, Chunliu Huang, Jing Liao, Yingzhao Wang, Yongyi Feng, Hongyu Li, Xiuying Liu, Lingdan Chen, Wei Yi, Xi Chen, Hong-Min Bai, Xinyu Wang, Yiyi Li, Lixiang Wang, Zhigang Liang, Xianwen Ren, Li Qiu, Yuan Hui, Qingling Zhang, Qibin Leng, Jun Chen, Guangshuai Jia
Summary: By analyzing the single-cell RNA sequencing and spatial transcriptomics of patients with glioblastoma multiforme (GBM) treated with neoadjuvant anti-PD-1 therapy, researchers identified a subpopulation of monocyte-derived tumor-associated macrophages that highly express the immunosuppressive SIGLEC9 gene and are resistant to anti-PD-1 treatment. Deletion of Siglece (murine homolog) resulted in suppressed tumor growth and improved survival in mouse models by activating CD4(+) T cells and CD8(+) T cells. Furthermore, Siglece deletion synergized with anti-PD-1/PD-L1 treatment to enhance antitumor efficacy.
Article
Pharmacology & Pharmacy
Zesheng Li, Bo Wang, Jianjian Wu, Lei Han
Summary: Tricyclic antidepressants are safe and reliable therapeutic agents that can be used for cancer treatment, especially glioblastoma. However, the specific mechanism by which they affect the tumor microenvironment of glioblastoma is still unclear.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Yin-Cheng Huang, Joseph Chieh-Yu Lai, Pei-Hua Peng, Kuo-Chen Wei, Kou-Juey Wu
Summary: This study identified GSTM1 as a significant prognostic marker for predicting survival in GBM patients using ATAC-seq and RNA-seq methods. Knockdown of GSTM1 led to decreased cell viability, cell cycle arrest, and reduced levels of phosphorylated NF-kB p65 and STAT3. Analysis of chromatin accessibility in patient samples could provide an independent biomarker for predicting patient survival.
CLINICAL EPIGENETICS
(2021)
Article
Cell Biology
Hailong Liu, Youliang Sun, Qian Zhang, Wei Jin, Renata E. Gordon, Yanyang Zhang, Jian Wang, Caihong Sun, Zeyuan John Wang, Xueling Qi, Junping Zhang, Boyuan Huang, Qiuping Gui, Hongyu Yuan, Ling Chen, Xiaodong Ma, Chuan Fang, Yong-qiang Liu, Xinguang Yu, Shiyu Feng
Summary: Limited understanding of the glioblastoma microenvironment and molecular mechanisms complicates the development of effective treatment strategies. This study unveils the correlation between SETD2 mutation and poor prognosis in IDH-WT adult glioblastoma patients, and identifies a specific subpopulation of high-grade glioma-associated microglia (HGG-AM) with pro-inflammatory and proliferative characteristics that interact with tumor cells to promote progression. The depletion of TGF-beta 1/TbRI significantly reduces HGG-AM density and suppresses tumor growth.
Article
Oncology
Antonio Omuro, Alba A. Brandes, Antoine F. Carpentier, Ahmed Idbaih, David A. Reardon, Timothy Cloughesy, Ashley Sumrall, Joachim Baehring, Martin van den Bent, Oliver Bahr, Giuseppe Lombardi, Paul Mulholland, Ghazaleh Tabatabai, Ulrik Lassen, Juan Manuel Sepulveda, Mustafa Khasraw, Elodie Vauleon, Yoshihiro Muragaki, Anna Maria Di Giacomo, Nicholas Butowski, Patrick Roth, Xiaozhong Qian, Alex Z. Fu, Yanfang Liu, Von Potter, Alexandros-Georgios Chalamandaris, Kay Tatsuoka, Michael Lim, Michael Weller
Summary: This study showed that TMZ + RT had better efficacy than NIVO + RT in newly diagnosed GBM patients with unmethylated MGMT promoter. However, no new safety signals were detected with NIVO in this study.
Article
Oncology
Giulia Cerretti, Diego Cecchin, Luca Denaro, Mario Caccese, Marta Padovan, Vittorina Zagonel, Giuseppe Lombardi
Summary: This study reports a case of a 42-year-old patient with BRAF(V600E) mutant and SOX2 amplification glioblastoma who showed a radiologic and metabolic complete response to personalized treatment with dabrafenib, trametinib, and silybin. Personalized treatment with BRAF and MEK inhibitors showed promising activity in patients with BRAF(V600E) mutant glioblastoma, and silybin may play an important role in reducing drug resistance, especially in patients with SOX2 amplification.
Article
Oncology
Andrew B. Lassman, Stephanie L. Pugh, Tony J. C. Wang, Kenneth Aldape, Hui K. Gan, Matthias Preusser, Michael A. Vogelbaum, Erik P. Sulman, Minhee Won, Peixin Zhang, Golnaz Moazami, Marian S. Macsai, Mark R. Gilbert, Earle E. Bain, Vincent Blot, Peter J. Ansell, Suvajit Samanta, Madan G. Kundu, Terri S. Armstrong, Jeffrey S. Wefel, Clemens Seidel, Filip Y. de Vos, Sigmund Hsu, Andres F. Cardona, Giuseppe Lombardi, Dmitry Bentsion, Richard A. Peterson, Craig Gedye, Veronique Bourg, Antje Wick, Walter J. Curran, Minesh P. Mehta
Summary: The use of depatux-m in newly diagnosed glioblastomas (GBMs) with epidermal growth factor receptor gene amplification (EGFR-amp) did not improve overall survival (OS), but showed a longer progression-free survival. There were safety risks associated with the treatment, leading to treatment discontinuation for some patients.
Article
Oncology
Emilie Le Rhun, Felix Boakye Oppong, Martin van den Bent, Wolfgang Wick, Alba A. Brandes, Martin J. B. Taphoorn, Michael Platten, Ahmed Idbaih, Paul M. Clement, Matthias Preusser, Vassilis Golfinopoulos, Thierry Gorlia, Michael Weller
Summary: This study retrospectively analyzed the incidence of lomustine-induced thrombocytopenia and its impact on treatment exposure and survival in patients with recurrent glioblastoma. The results showed that thrombocytopenia induced by lomustine is a major limitation to adequate exposure to lomustine chemotherapy and is associated with inferior progression-free survival, particularly in patients with MGMT promoter-methylated tumors.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Nour-El-Houda Mourksi, Cecile Dalban, Amelie Colombe-Vermorel, Laetitia Odeyer, Valentin Simioni, Jean-Sebastien Frenel, Michel Fabbro, Fernando Bazan, Sophie Abadie-Lacourtoisie, Elodie Coquan, Severine Martinez, Gwenaelle Garin, Severine Tabone-Eglinger, Isabelle Treilleux, Sylvie Chabaud, David Perol, Isabelle Ray-Coquard, Pierre-Etienne Heudel, Jean-Jacques Diaz, Virginie Marcel
Summary: The resistance of advanced hormone-dependent endometrial carcinoma to endocrine therapy is a global clinical issue. A recent study found that the combination of Vistusertib (a mTOR inhibitor) and Anastrozole (an aromatase inhibitor) improves progression-free rate compared to Anastrozole alone. This study evaluates the potential use of ribosome biogenesis (RiBi) factors as innovative markers for patient selection and treatment response prediction.
MOLECULAR ONCOLOGY
(2023)
Article
Health Care Sciences & Services
Anne-Sophie Baudry, Laurence Vanlemmens, Anne Congard, Aurelie Untas, Carine Segura-Djezzar, Claudia Lefeuvre-Plesse, Florence Coussy, Severine Guiu, Jean-Sebastien Frenel, Baptiste Sauterey, Sonya Yakimova, Veronique Christophe
Summary: This study examines the impact of emotional competence on the quality of life (QoL) and anxiety and depression symptoms of partners of women with breast cancer. The results show that emotional competence has direct and indirect effects on partners' QoL and psychological symptoms. These findings highlight the importance of considering emotional processes in the adjustment and support of partners, and suggest integrating emotional competence in future health models and psychosocial interventions.
QUALITY OF LIFE RESEARCH
(2023)
Article
Oncology
Michael Weller, Emilie Le Rhun, Martin Van den Bent, Susan M. Chang, Timothy F. Cloughesy, Roland Goldbrunner, Yong-Kil Hong, Rakesh Jalali, Michael D. Jenkinson, Giuseppe Minniti, Motoo Nagane, Evangelia Razis, Patrick Roth, Roberta Ruda, Ghazaleh Tabatabai, Patrick Y. Wen, Susan C. Short, Matthias Preusser
Summary: The European Association of Neuro-Oncology (EANO) has developed recommendations for the prevention, diagnosis, and management of adverse effects and complications in adult primary brain central nervous system (CNS) tumor patients. The recommendations cover surgery, radiotherapy, and pharmacotherapy, including dose adaptations, interruptions, and reexposure, and summarize unnecessary, inactive, or contraindicated interventions. This consensus paper serves as a reference for standard therapy in clinical trials and clinical practice.
Review
Oncology
Felix Sahm, Sebastian Brandner, Luca Bertero, David Capper, Pim J. French, Dominique Figarella-Branger, Felice Giangaspero, Christine Haberler, Monika E. Hegi, Bjarne W. Kristensen, Kathreena M. Kurian, Matthias Preusser, Bastiaan B. J. Tops, Martin van den Bent, Wolfgang Wick, Guido Reifenberger, Pieter Wesseling
Summary: In the 5th edition of the WHO CNS tumor classification, molecular characteristics have become important diagnostic criteria for many CNS tumor types. This guideline focuses on the methods used for diagnosing gliomas, glioneuronal, and neuronal tumors using informative molecular markers. Various molecular methods are discussed, including next-generation sequencing, methylation profiling, and immunohistochemistry. The guideline also covers the analysis of MGMT promoter methylation status, and provides an overview of the advantages, limitations, and requirements of different assays. The importance of molecular diagnostic testing in neuro-oncology is emphasized, along with discussions on clinical relevance, accessibility, cost, and ethical aspects.
Article
Oncology
Helene Francois-Martin, Audrey Lardy-Cleaud, Barbara Pistilli, Christelle Levy, Veronique Dieras, Jean-Sebastien Frenel, Severine Guiu, Marie-Ange Mouret-Reynier, Audrey Mailliez, Jean-Christophe Eymard, Thierry Petit, Mony Ung, Isabelle Desmoulins, Paule Augereau, Thomas Bachelot, Lionel Uwer, Marc Debled, Jean-Marc Ferrero, Florian Clatot, Anthony Goncalves, Michael Chevrot, Sylvie Chabaud, Paul Cottu
Summary: This study evaluated the impact of everolimus-based therapy on overall survival in a national cohort of breast cancer patients. The findings suggest that everolimus may improve overall survival in advanced hormone receptor positive, HER2 negative breast cancer, but its usage is currently underutilized in clinical practice.
Article
Clinical Neurology
Sybren L. N. Maas, Philipp Sievers, Damien C. Weber, Michael Weller, Martin J. van den Bent, Maximilian J. Mair, Johan M. Kros, Fransesca Carparrotti, Andreas von Deimling, Villa Freixa Salvador, Saskia Marguerite Peerdeman, Jose Casas-Martin, Thierry Gorlia, Felix Sahm, Matthias Preusser
ACTA NEUROPATHOLOGICA
(2023)
Article
Oncology
Ioannis Ntafoulis, Anne Kleijn, Jie Ju, Kevin Jimenez-Cowell, Federica Fabro, Michelle Klein, Romain Tching Chi Yen, Rutger K. Balvers, Yunlei Li, Andrew P. Stubbs, Trisha V. Kers, Johan M. Kros, Sean E. Lawler, Laurens V. Beerepoot, Andreas Kremer, Ahmed Idbaih, Maite Verreault, Annette T. Byrne, Alice C. O'Farrell, Kate Connor, Archita Biswas, Manuela Salvucci, Jochen H. M. Prehn, Diether Lambrechts, Gonca Dilcan, Francesca Lodi, Ingrid Arijs, Martin J. van den Bent, Clemens M. F. Dirven, Sieger Leenstra, Martine L. M. Lamfers
Summary: This study found that patient-derived glioma stem-like cells (GSCs) retain patient-unique gene expressions despite the loss of their natural environment. Drug screening using GSCs predicted patient response to temozolomide (TMZ) more specifically than the MGMT status alone. Transcriptome analysis identified potential biomarkers for TMZ sensitivity.
BRITISH JOURNAL OF CANCER
(2023)
Review
Biochemistry & Molecular Biology
Gerardo Caruso, Aristide Nanni, Antonello Curcio, Giuseppe Lombardi, Teresa Somma, Letteria Minutoli, Maria Caffo
Summary: An increase in brain tumor incidence has been observed in industrialized countries, leading to interest in the study of heavy metals and their presence in the environment. Accumulation of heavy metals in the body could increase the risk of various pathologies, including brain tumors, through the generation of reactive oxygen species. Iron, cadmium, lead, nickel, chromium, and mercury levels are significantly elevated in patients with gliomas. This study aims to explore the correlation between heavy metals, their presence in the environment, and glioma tumorigenesis, and provides a literature review.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Editorial Material
Oncology
Patrick Y. Wen, Martin van den Bent, Michael A. Vogelbaum, Susan M. Chang
Article
Biochemistry & Molecular Biology
Khrystany T. Isebia, Martijn P. Lolkema, Guido Jenster, Ronald de Wit, John W. M. Martens, Job van Riet
Summary: This study found that in metastatic castration-resistant prostate cancer, in addition to AR-V7, AR45 and AR-V3 were also commonly seen AR splice variants. The presence of any AR-Vs may be associated with higher AR expression. These AR-Vs could potentially serve as predictive and prognostic biomarkers in metastatic castration-resistant prostate cancer, similar or complementary to AR-V7.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)